recovery

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

...costs and improve patient diagnosis, treatment and recovery time. Complete Blood Count (CBC) and CRP measurement are two possible hematological tests that could be relocated from the clinical laboratory to the patients bedside. CBC forms an integral part of hematology and guides numerous therapeutic interven...

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

...ies ofFactor IX that may improve the half-life and recovery compared tocommercially available recombinant Factor IX. The company iscurrently refining its cGMP manufacturing process to maximize thebiological properties of its clinical product based on thesestudies. "Inspiration Biopharmaceuticals is seeking...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

...loidplaque in the brain, accompanied by a complete recovery of memoryback to baseline (p=0.002), as shown in a...n, CEO of Samaritan Pharmaceuticals stated,"Memory recovery in rats is a lot simpler than curing Alzheimer'sdisease in people but these study results are extrem...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

...ransplantation without the associated sideeffects, recovery time and expense," said Maria-Victoria Mateos,M.D., Ph.D., Grupo Espanol de Multiple Myeloma. "With VELCADE addedto this combination, we now are able to offer all patients,including those who historically could not have a transplant, analternative th...

BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting

...d mediaformulations improved the post-preservation recovery of CD34+ andcolony-forming cells. We will continue our evaluations andvalidation of BioLife's products with the hope to incorporateCryoStor into our clinical applications." BioLife Chief Executive Mike Rice remarked: "We're very pleasedthat world-cl...

CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS

...aPhase II clinical trial for arimoclomol in stroke recovery in thefirst half of 2008, subject to FDA clearance. The Company has alsoannounced plans to commence a Phase II clinical trial with its nextdrug candidate, iroxanadine, for diabetic foot ulcers in the firsthalf of 2008, subject to FDA clearance. In ad...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine

...eappearanceof T2 and achieved significantly faster recovery of the T4/T1 ratioto 0.9 compared with neostigmine. Median time to recovery was 1.4minutes (0.9-5.4; p<0.0001) for sugammadex versus 17.6 minutes(3.7-106.9; p<0.0001) f...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine

...eappearanceof T2 and achieved significantly faster recovery of the T4/T1 ratioto 0.9 compared with neostigmine. Median time to recovery was 1.4minutes (0.9-5.4; p<0.0001) for sugammadex versus 17.6 minutes(3.7-106.9; p<0.0001) f...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...ing one completeremission with incomplete platelet recovery (CRp), one completeremission in a patient who demonstrated partial but incompleterecovery of normal hematopoietic blood elements (CRi) and onepartial response (PR). Additionally, in the twice-weekly 40 mg/m2dose cohort, one of three patients had blas...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

...omplete responses with incomplete peripheral count recovery (CR-i)and one partial response (PR). Significant HDAC activity inhibitionwas seen in most patients. Enrollment is ongoing and expected to be complete by year end.Subsequent studies are planned including potentially largerrandomized trials in either ...

DP-b99 Phase IIb Trial Results to be Presented at the European Stroke Conference

...by the modified Rankin scale or NIHSS. The day 90 recovery rate in the DP-b99 treated group was twotimes high...oms. The data indicate that the effect ofDP-b99 on recovery was uniform across the full 9h window,confirming the wide therapeutic window for DP-b99. The favora...

ProtoKinetix's AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells

...ition of 2mg/ml of AAGP(TM) resulted in an amazing recovery of87%. Traditional recovery rates after cryopreservation with DMSO(Dimethyl Sulphoxide) are typically between 30% and 40%. Stem ...

DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia

...s. This option appears muchsafer and requires less recovery time." DUSA provided theLevulan(R) to support this study. Barrett's esophagus Barrett's esophagus is a precancerous condition in which thelining of the esophagus is replaced with abnormal cells that couldlead to dysplasia, and ultimately, esophagea...

Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting

...GF ZFP TF had a statistically significanteffect on recovery of hind-limb function as well as a number ofother measures of nerve integrity and health. The work was carried out in the laboratory of Dr. MichaelFehlings who holds the Krembil Chair in Neural Repair andRegeneration at the Krembil Neuroscience Cent...

Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex

...inical andpathological disease reversal and tissue recovery were observedwith Symadex treatment. At the same time, Symadex did not affectcirculating immune cell numbers, suggesting that it does not act asa general immunosuppressant. "Symadex' ability to reverse chronic autoimmune disease in thisanimal mode...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

... loss of myelin(demyelination), variable levels of recovery between events, andirregular periods of remission. When recovery from relapse isincomplete, patients with RRMS gradually accumulate irreversibleneurological damage a...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

... loss of myelin(demyelination), variable levels of recovery between events, andirregular periods of remission. When recovery from relapse isincomplete, patients with RRMS gradually accumulate irreversibleneurological damage a...

CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies

...candidatearimoclomol significantly accelerated the recovery of sensory andmotor function in an experimental ra...fter strokewere approximately half-way to complete recovery by day seven afterstroke, whereas motor skills of untreated animals were unimproved.These data sugge...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

... solution, but inclusion of P80 or LHB promoted recovery of 80 to 100 percent of the agent for up to 24 hours. ORI minimal inhibitory concentrations (MICs) for S. aureus and E. faecalis were 16- to 32- fold lower in the presence of P80, compared with no MIC impact on vancomycin ...

Latest NIMH Study on Bipolar Disorder

...callywell in a given month and had higher rates of recovery thanindividuals only receiving collaborative care. This is a call toaction for access to these hard-to-find interventions. The implications of this study are twofold. First, there needsto be more training programs that offer these psychosocialinte...

Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection

...lortim both protected againstinfection and induced recovery and survival in animals exposed tolethal doses of inhalation anthrax spores. A study in non-humanprimates has demonstrated the potency of Valortim in this modelusing the potentially most clinically-useful intramuscular route ofadministration. In this...

Study Sheds Light on Medication Treatment Options for Bipolar Disorder

...cebostayed well long enough to meet the eight-week recovery standard,indicating no difference between adding an antidepressant or addingplacebo. In addition, about 10 percent of each group experiencedemerging symptoms of mania, indicating that the antidepressants didnot trigger a manic switch any more than pl...

Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection

...lortim both protected againstinfection and induced recovery and survival in animals exposed tolethal doses of inhalation anthrax spores. A study in non-humanprimates has demonstrated the potency of Valortim in this modelusing the potentially most clinically-useful intramuscular route ofadministration. In this...

BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality

... the mechanical strength of theheart muscle during recovery and repair thereby preventingpathological enlargement of the left ventricle after the heartattack. BL-1040 degrades naturally six weeks after injection. Patients who have undergone an acute MI (AMI) with severe heartdamage are the most likely to ben...